atopic dermatitis

News

Lilly wins new FDA approval for eczema drug Ebglyss

Lilly's Ebglyss has claimed an FDA approval for less-frequent maintenance dosing that could give it an edge over market leader Dupixent.

News

Sanofi's bispecific lunsekimig has mixed readouts in phase 2

Sanofi's IL-13 and TSLP-targeting bispecific lunsekimig wins two, loses one, in readouts from its midstage clinical trials programme.

News

Cancer risk scuppers Kyowa Kirin's autoimmune disease drug

Kyowa Kirin has terminated all clinical trials of its anti-OX40L antibody rocatinlimab, after cases of cancer were seen in patients taking the drug.

News

MSD and Mayo Clinic team up on AI drug discovery

MSD has signed an industry-first deal with the Mayo Clinic that will allow it to use the health system's genomic and clinical data for drug discovery.

News

Sanofi plans amlitelimab dermatitis filing after new readout

Sanofi has said it will press ahead with regulatory filings for atopic dermatitis candidate amlitelimab, despite mixed data in phase 3.

News

J&J abandons trial of atopic dermatitis drug

J&J has discontinued a phase 2 trial of one of its pipeline candidates for atopic dermatitis, acquired in 2024 in a $1.25bn takeover deal.

Lilly wins new FDA approval for eczema drug Ebglyss

Sanofi's bispecific lunsekimig has mixed readouts in phase 2

Cancer risk scuppers Kyowa Kirin's autoimmune disease drug

MSD and Mayo Clinic team up on AI drug discovery

Sanofi plans amlitelimab dermatitis filing after new readout

J&J abandons trial of atopic dermatitis drug

UK offers meningitis jab to young people after outbreak

Discover a new era of healthcare panel engagement: Grounded ...

atopic dermatitis

Editor's Picks